Live Marvell Technology Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow MiNK Therapeutics, Inc.

Get SEC filing alerts via email and in your feed for MiNK Therapeutics, Inc.

INKT

MiNK Therapeutics, Inc.

About MiNK Therapeutics, Inc.

MiNK Therapeutics, Inc. develops allogeneic, off-the-shelf invariant natural killer T (iNKT) cell therapies for cancer and immune-mediated diseases. Its platform leverages native and engineered iNKT cells to target tumors, treat viral ARDS, and prevent graft-versus-host disease. The company focuses on scalable manufacturing, proprietary cell engineering, and strategic collaborations to deliver innovative immunotherapies with broad applicability and potential for rapid clinical impact.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from MiNK Therapeutics, Inc.

1
1
MiNK Therapeutics, Inc. MiNK Therapeutics Reports $2.74 Million Net Loss in Q1 2026, Advances Clinical Programs

Via official filing (AI summary) | 23 days ago | 0 comments

2
1
MiNK Therapeutics, Inc. MiNK Therapeutics Reports $12.5 Million Net Loss for Fiscal Year 2025

Via official filing (AI summary) | 2 months ago | 0 comments

3
1
MiNK Therapeutics, Inc. MiNK Therapeutics Reports $2.9 Million Net Loss and Improved Cash Position in Latest 10-Q

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
MiNK Therapeutics, Inc. MiNK Therapeutics Reports $4.2 Million Net Loss in Q2 2025, Sees Decrease in Total Assets

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
MiNK Therapeutics, Inc. MiNK Therapeutics Reports $2.77 Million Net Loss in Q1 2025, Focuses on iNKT Cell Therapies

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
MiNK Therapeutics, Inc. MiNK Therapeutics Reports $10.8 Million Net Loss for Fiscal Year 2024, Advances Clinical Trials

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
MiNK Therapeutics, Inc. MiNK Therapeutics Reports Financial Results, Reduces Losses and Increases Cash Reserves

Via official filing (AI summary) | over 1 year ago | 0 comments